The response rate in this trial and clinically meaningful duration of response and survival led to regular FDA approval of enasidenib 100 mg daily as monotherapy for IDH2-mutated AML in the relapsed/refractory setting. This evidence concerns the gene IDH2 and acute myeloid leukemia.